4 Ways AstraZeneca plc Will Continue To Lead The Biotechnology Sector

How does AstraZeneca plc (LON: AZN) compare to its sector peers?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Right now I’m comparing some of the most popular companies in the FTSE 100 with their sector peers in an attempt to establish which one is the more attractive investment.

Today I’m looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US)

Valuation

First off, let’s take a look at AstraZeneca’s valuation in relation to its sector peers. AstraZeneca currently trades at a historic P/E ratio of 7.9, below the biotechnology sector average of 17.1.

However, as the company is set to lose the exclusive manufacturing rights to a number of treatments during the next few years, City analysts expect AstraZeneca’s earnings to fall next year. As a result, AstraZeneca’s forward P/E ratio is 9.9 — still lower than its sector peers. 

Balance sheet

  Net-debt-to-assets Interest cover by operating profit
AstraZeneca 5% 18x
GlaxoSmithKline 34% 10x
Shire 5%

Although AstraZeneca’s earnings are expected to decline during the next few years, the company is well placed to ride out this trend.

Indeed, AstraZeneca’s balance sheet is strong and net debt only amounts to 5% of assets. What’s more, AstraZeneca is able to cover its interest costs 18 times by operating profit.

This solid financial position has given AstraZeneca a great spring-board for the company to be able to acquire peers and treatments to bolster its flagging pipeline.

In particular, since October last year AstraZeneca has acquired five smaller peers, signed five collaboration deals and commenced two licence deals. Half of these deals are related to cancer treatments.

Company’s performance

  Earnings growth past five years Net profit margin
AstraZeneca 26% 14%
GlaxoSmithKline 8% 16%
Shire 317% 13%

Moreover, AstraZeneca’s earnings have expanded faster than those of that of close peer GlaxoSmithKline during the past five years. That said, AstraZeneca’s net profit margin, which currently sits at 14%, is down from its five-year high of 30% seen back in 2011.

Still, AstraZeneca’s recent acquisitions and collaborations show that management is working hard to drive the company’s growth and profitability back to historic levels. 

Dividends

  Current Dividend Yield Current dividend cover Projected annual dividend growth for next two years.
AstraZeneca 5.5% 2.3 2%
GlaxoSmithKline 4.7% 1.5 6%
Shire 0.4% 7.7 38%
Sector average 4.5% 1.3  

Furthermore, AstraZeneca currently offers the largest dividend yield out of its close peers. Having said that, City analysts expect AstraZeneca’s payout to expand only 4% over the next two years.

Nonetheless, AstraZeneca’s payout is covered more than twice by earnings, which gives me confidence that the payout will be maintained even if earnings fall. 

Foolish summary

All in all, AstraZeneca is currently trading at a low valuation in relation to peers, has a clean balance sheet and is working hard to drive growth.

So overall, I feel that AstraZeneca is a much stronger share than its peers. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Rupert does not own any share mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

3 ISA strategies to consider

Christopher Ruane weighs some pros and cons of three different investment strategies and explains how he manages his Stocks and…

Read more »

Investing Articles

Should I buy more Ferrari shares for my SIPP?

Ferrari stock has done very well in this investor's SIPP portfolio. But is it attractively priced to warrant investing more…

Read more »

Young woman holding up three fingers
Investing Articles

My simple 3-step passive income plan for 2025

Ben McPoland outlines a straightforward plan to sustainably increase his passive income from dividend stocks in the New Year.

Read more »

Investing Articles

Are UK penny stocks set to skyrocket in 2025?

With UK growth shares becoming thinner on the ground, I think growth investors might turn to penny stocks in the…

Read more »

Investing Articles

Are these the best FTSE 250 dividend shares to consider buying for 2025?

When looking for income shares to buy, it's worth checking out the whole stock market and not just the traditional…

Read more »

Investing Articles

Can the FTSE 100 hit 10,000 in 2025? Here’s what the experts say

It's guessing game time again, as we all get out our crystal balls and try to predict where the FTSE…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

£1,000 parked in the FTSE 100 at the start of the year, would be worth this much now

Despite liking the profitable performance of the FTSE 100 index so far this year, Christopher Ruane explains why he bought…

Read more »

Investing Articles

Could British American Tobacco shares actually provide a long-term second income?

If next-generation products can replace lost cigarette earnings, then a FTSE 100 stock with an 8% dividend yield could be…

Read more »